Correlation Engine 2.0
Clear Search sequence regions

  • antibodies (1)
  • CGRP (6)
  • CGRP receptor (2)
  • humans (1)
  • ligand (1)
  • patients (1)
  • receptor (2)
  • Sizes of these terms reflect their relevance to your search.

    The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine has promoted a new era in migraine treatment: CGRP antagonism. Two classes of medications are currently available: small molecules targeting the CGRP receptor and monoclonal antibodies targeting the CGRP receptor or CGRP ligand. The revolution of these medications is represented by blurring the borders between acute and preventive treatments, episodic and chronic migraine, naïve and refractory patients and even between migraine and other headache disorders. Copyright © 2020 Elsevier Inc. All rights reserved.


    Edoardo Caronna, Amaal J Starling. Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine. Neurologic clinics. 2021 Feb;39(1):1-19

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33223077

    View Full Text